Cited by 940SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Open access

Lumley, Sheila F., O’Donnell, Denise, Stoesser, Nicole E., Matthews, Philippa C., Howarth, Alison, Hatch, Stephanie B., Marsden, Brian D., Cox, Stuart, James, Tim, Warren, Fiona, Peck, Liam J., Ritter, Thomas G., de Toledo, Zoe, Warren, Laura, Axten, David, Cornall, Richard J., Jones, E. Yvonne, Stuart, David I., Screaton, Gavin, Ebner, Daniel, Hoosdally, Sarah, Chand, Meera, Crook, Derrick W., O’Donnell, Anne-Marie, Conlon, Christopher P., Pouwels, Koen B., Walker, A. Sarah, Peto, Tim E.A., Hopkins, Susan, Walker, Timothy M., Jeffery, Katie, Eyre, David W.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2034545PMC PMC7781098

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. METHODS: We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time. RESULTS: A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P = 0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status. CONCLUSIONS: The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2034545

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Vaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Genomic evidence for reinfection with SARS-CoV-2: a case study
Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N. F., Gorzalski, A. J., Laverdure, C., Verma, S. C., Rossetto, C. C., Jackson, D. K., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30764-7 · Cited by 755
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 2

Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J Infect Dis 2020 November 3 (Epub ahead of print).33140086
To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020 August 25 (Epub ahead of print).32840608

Sorted by citations

Items 301–400 of 913

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
Vacharathit, V., Srichatrapimuk, S., Manopwisedjaroen, S., Kirdlarp, S., Srisaowakarn, C., Setthaudom, C., Inrueangsri, N., Pisitkun, P., Kunakorn, M., Hongeng, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.021 · Cited by 22
Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors
Adi, W., Biswas, D., Shelef, M. A., & Yesilköy, F. (2022) · Biomedical Optics Express · doi:10.1364/boe.454919 · Cited by 23
Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2
Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 22
Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination
Lippi, G., Sciacovelli, L., Trenti, T., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0038 · Cited by 22
New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil
Goes, L. R., Siqueira, J. D., Garrido, M. M., Alves, B. M., Pereira, A. C. P. M., Cicala, C., Arthos, J. A., Viola, J. P. B., & Soares, M. A. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104998 · Cited by 21
Rate of reinfections after SARS-CoV-2 primary infection in the population of an Italian province: a cohort study
Flacco, M. E., Martellucci, C. A., Soldato, G., Carota, R., Fazii, P., Caponetti, A., & Manzoli, L. (2021) · Journal of Public Health · doi:10.1093/pubmed/fdab346 · Cited by 21
Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset
Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100727 · Cited by 23
Measuring Work-related Risk of Coronavirus Disease 2019 (COVID-19): Comparison of COVID-19 Incidence by Occupation and Industry—Wisconsin, September 2020 to May 2021
Pray, I. W., Grajewski, B. A., Morris, C. R., Modji, K. K. S., DeJonge, P. M., McCoy, K. E., Tomasallo, C. D., DeSalvo, T. E., Westergaard, R. P., & Meiman, J. G. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac586 · Cited by 21
Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection
Franchi, M., Pellegrini, G., Cereda, D., Bortolan, F., Leoni, O., Pavesi, G., Galli, M., Valenti, G., & Corrao, G. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.05.018 · Cited by 21
Accurate point-of-care serology tests for COVID-19
Schuler, C. F., IV, Gherasim, C., O’Shea, K. M., Manthei, D. M., Chen, J., Giacherio, D., Troost, J. P., Baldwin, J. L., & Baker, J. R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248729 · Cited by 21
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies
Schuler, C. F., IV, Gherasim, C., O’Shea, K. J., Manthei, D. M., Chen, J., Zettel, C., Troost, J. P., Kennedy, A. A., Tai, A. W., Giacherio, D. A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00087-21 · Cited by 22
Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
Fakhroo, A. D., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2021) · Vaccines · doi:10.3390/vaccines9101168 · Cited by 21
SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation
Lamerton, R. E., Marcial‐Juárez, E., Faustini, S. E., Pérez-Toledo, M., Goodall, M. D., Jossi, S. E., Newby, M. L., Chapple, I., Dietrich, T., Veenith, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838780 · Cited by 20
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severityPreprint
Laing, E. D., Epsi, N. J., Richard, S. A., Samuels, E. C., Wang, W., Vassell, R. A., Ewing, D. F., Herrup, R., Sterling, S. L., Lindholm, D. A., et al. (2021) · medRxiv · doi:10.1101/2021.04.27.21256207 · Cited by 20
Analysis of Neutralizing Antibody Levels in Children and Adolescents Up to 16 Months After SARS-CoV-2 Infection
Yung, C. F., Saffari, S. E., Mah, S. Y. Y., Tan, N. W. H., Chia, W., Thoon, K. C., & Wang, L. (2022) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.3072 · Cited by 19
Incidence and Prevalence of Coronavirus Disease 2019 Within a Healthcare Worker Cohort During the First Year of the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic
Doernberg, S. B., Holubar, M. K., Jain, V., Weng, Y., Lu, D., Bollyky, J., Sample, H. A., Huang, B., Craik, C. S., Desai, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac210 · Cited by 19
Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs
Ronchini, C., Gandini, S., Pasqualato, S., Mazzarella, L., Facciotti, F., Mapelli, M., IEO Covid Team, Frigè, G., Passerini, R., Pase, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263014 · Cited by 19
Evaluation of the performance of SARS‐CoV‐2 antibody assays for a longitudinal populationbased study of COVID‐19 spread in St. Petersburg, Russia
Барчук, А. А., Shirokov, D., Sergeeva, M. V., Турсун-заде, Р. Т., Dudkina, O., Tychkova, V., Barabanova, L., Skougarevskiy, D., & Danilenko, D. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27126 · Cited by 18
Highly Effective Naturally Acquired Protection Against COVID-19 Persists for at Least 1 Year: A Meta-Analysis
Petráš, M. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.042 · Cited by 18
SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma
Itell, H. L., Weight, H., Fish, C. S., Logue, J. K., Franko, N., Wolf, C. R., McCulloch, D. J., Galloway, J., Matsen, F. A., IV, Chu, H. Y., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01298-21 · Cited by 18
Testing for SARS-CoV-2: lessons learned and current use cases
Theel, E. S., Kirby, J. E., & Pollock, N. R. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-23 · Cited by 18
A reasoned approach towards administering COVID‐19 vaccines to pregnant women
Pramanick, A., Kanneganti, A., Wong, J. L. J., Li, S. W., Dimri, P. S., Mahyuddin, A. P., Kumar, S., Illanes, S. E., Chan, J. K. Y., Su, L., et al. (2021) · Prenatal Diagnosis · doi:10.1002/pd.5985 · Cited by 19
Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study
Jones, H. E., Mulchandani, R., Taylor‐Phillips, S., Ades, A. E., Shute, J., Perry, K. R., Chandra, N. L., Brooks, T. J. G., Charlett, A., Hickman, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103414 · Cited by 19
Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection
Banham, G. D., Godlee, A., Faustini, S. E., Cunningham, A. F., Richter, A. G., Harper, L., & on behalf of the COVID-HD Birmingham Study Group (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020188 · Cited by 18
Antibody responses to COVID‐19 vaccines in older adults
Soytaş, R. B., Cengız, M., İslamoğlu, M. S., Uysal, B. B., Yavuzer, S., & Yavuzer, H. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27531 · Cited by 18
An update on host immunity correlates and prospects of re-infection in COVID-19
Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 20
Redox Homeostasis and Immune Alterations in Coronavirus Disease-19
Bellanti, F., Buglio, A. L., & Vendemiale, G. (2022) · Biology · doi:10.3390/biology11020159 · Cited by 18
Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Kannenberg, J., Trawinski, H., Henschler, R., Buhmann, R., Hönemann, M., & Jassoy, C. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac034 · Cited by 20
Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers
Costa, C. S., Migliore, E., Galassi, C., Scozzari, G., Ciccone, G., Coggiola, M., Pira, E., Scarmozzino, A., Valle, G. L., Cassoni, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10030474 · Cited by 18
COVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant Recipients
Moreno, N. F., McAdams, R., Goss, J. A., & Galván, N. T. N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00366-1 · Cited by 18
The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers
Racine, É., Boivin, G., Longtin, Y., McCormack, D., Decaluwe, H., Savard, P., Cheng, M. P., Hamelin, M., Carbonneau, J., Tadount, F., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12997 · Cited by 18
PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature
AbdelMassih, A. F., Menshawey, R., Ismail, J. H., Husseiny, R., Husseiny, Y. M., Yacoub, S., Kamel, A., Hozaien, R., Yacoub, E., Menshawey, E., et al. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00179-2 · Cited by 17
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age
Tanner, R., Starr, N., Chan, G., Dempsey, E., Heffernan, E., Newman, E., O'Neill, J., Hannan, M. M., Lynch, B., & Joyce, E. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.01.005 · Cited by 17
Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain
Pérez‐Olmeda, M., Saugar, J. M., Fernández-García, A., Pérez‐Gómez, B., Pollán, M., Avellón, A., Pastor‐Barriuso, R., de Larrea, N. F., Martín, M., Cruz, I., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105130 · Cited by 18
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2
Wahezi, D. M., Lo, M. S., Rubinstein, T. B., Ringold, S., Ardoin, S. P., Downes, K. J., Jones, K. B., Laxer, R. M., Madan, R. P., Mudano, A. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41772 · Cited by 17
Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection
Manuylov, V. A., Burgasova, O., Borisova, O. V., Васильевна, С. С., Vasina, D. V., Grigoriev, I. V., Kudryashova, A. M., Semashko, M. A., Сергеевич, Ч. Б., Сергеевна, Х. О., et al. (2022) · Viruses · doi:10.3390/v14030617 · Cited by 19
Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility
Rosadas, C., Khan, M., Parker, E. L., Marchesin, F., Katsanovskaja, K., Sureda-Vives, M., Fernández, N., Randell, P. A., Harvey, R., Lilley, A., et al. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114475 · Cited by 17
Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases
Poparn, H., Srichumpuang, C., Sosothikul, D., Jantarabenjakul, W., Lauhasurayotin, S., Techavichit, P., Chiangthong, K., & Poovorawan, Y. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.6.2049 · Cited by 17
Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study
Rovida, F., Cassaniti, I., Percivalle, E., Sarasini, A., Paolucci, S., Klersy, C., Cutti, S., Novelli, V., Marena, C., Luzzaro, F., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.003 · Cited by 16
Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Presence of Anti–SARS-CoV-2 Antibodies Among University Student Dormitory Residents, September–November 2020
Segaloff, H. E., Cole, D., Rosenblum, H. G., Lee, C. C., Morgan, C. N., Remington, P., Pitts, C., Kelly, P., Baggott, J., Bateman, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab405 · Cited by 16
Immune Responses against SARS-CoV-2—Questions and Experiences
Mangge, H., Kneihsl, M., Schnedl, W. J., Sendlhofer, G., Curcio, F., & Domenis, R. (2021) · Biomedicines · doi:10.3390/biomedicines9101342 · Cited by 16
SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract
Hansen, F., Meade-White, K. D., Clancy, C. S., Rosenke, R., Okumura, A., Hawman, D. W., Feldmann, F., Kaza, B., Jarvis, M. A., Rosenke, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110515 · Cited by 16
SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection
Baerends, E. A. M., Hvidt, A. K., Reekie, J., Søgaard, O. S., Stærke, N. B., Raben, D., Nielsen, H. I., Petersen, K. T., Juhl, M. R., Johansen, I. S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107621 · Cited by 16
Anti-SARS-CoV-2 Antibody Testing: Role and Indications
Mink, S., & Fraunberger, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247575 · Cited by 16
Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned
Poljak, M., Oštrbenk, A., Štrumbelj, E., Vodičar, P. M., Vehovar, V., Rus, K. R., Korva, M., Knap, N., Seme, K., Petrovec, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.03.009 · Cited by 16
Generation of somatic mitochondrial DNA-replaced cells for mitochondrial dysfunction treatment
Maeda, H., Kami, D., Maeda, R., Shikuma, A., & Gojo, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-90316-1 · Cited by 16
Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers
Iversen, K. K., Kristensen, J. H., Hasselbalch, R. B., Pries‐Heje, M. M., Nielsen, P. B., Knudsen, A. D., Fogh, K., Norsk, J. B., Andersen, O., Fischer, T. K., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.005 · Cited by 16
Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark
Johannesen, C. K., Rezahosseini, O., Gybel‐Brask, M., Kristensen, J. H., Hasselbalch, R. B., Pries‐Heje, M. M., Nielsen, P. B., Knudsen, A. D., Fogh, K., Norsk, J. B., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00904-21 · Cited by 16
Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient
Klein, J., Brito, A. F., Trubin, P. A., Lu, P., Wong, P., Alpert, T., Peña-Hernández, M. A., Haynes, W. A., Kamath, K., Liu, F., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab553 · Cited by 16
The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries
Ferreira, C. D. S., Dantés, H. G., Bellei, N., López, E. L., Crespo, K. A. N., O’Ryan, M., & Villegas, J. (2021) · Viruses · doi:10.3390/v13122391 · Cited by 16
Coronavirus disease 2019 (COVID-19) vaccine intentions and uptake in a tertiary-care healthcare system: A longitudinal study
Evans, C. T., DeYoung, B. J., Gray, E., Wallia, A., Ho, J., Carnethon, M. R., Zembower, T., Hirschhorn, L. R., & Wilkins, J. T. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.523 · Cited by 16
Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Dan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 16
SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
Richardson, J. R., Götz, R., Mayr, V., Lohse, M. J., Holthoff, H., & Ungerer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266701 · Cited by 16
Bistability in deterministic and stochastic SLIAR-type models with imperfect and waning vaccine protection
Arino, J., & Milliken, E. (2022) · Journal of Mathematical Biology · doi:10.1007/s00285-022-01765-9 · Cited by 16
Post-COVID-19 and Post-COVID-19 Vaccine Arthritis, Polymyalgia Rheumatica and Horton’s Arteritis: A Single-Center Assessment of Clinical, Serological, Genetic, and Ultrasonographic Biomarkers
Bandinelli, F., Pagano, M., & Vallecoccia, M. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247563 · Cited by 16
An immune correlate of SARS-CoV-2 infection and severity of reinfectionsPreprint
Maier, H. E., Balmaseda, Á., Ojeda, S., Cerpas, C., Sánchez, N., Plazaola, M., van Bakel, H., Kubale, J., López, R., SABORÍO, S. I., et al. (2021) · medRxiv · doi:10.1101/2021.11.23.21266767 · Cited by 16
Clinical and Laboratory Findings in Patients With Potential Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection, May–July 2020
Lee, J. T., Hesse, E. M., Paulin, H. N., Datta, D., Katz, L. S., Talwar, A., Chang, G., Galang, R. R., Harcourt, J. L., Tamin, A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab148 · Cited by 15
Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
Ferguson, J., Murugesan, K., Banaei, N., & Liu, A. Y. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.06.054 · Cited by 15
Rethinking the evidence on COVID-19 in Africa
Bejon, P., Agweyu, A., Ochola‐Oyier, L. I., Hamaluba, M., Kamuya, D., Kinyanjui, S., & Barasa, E. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00071-4 · Cited by 15
SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids
Trevisan, M., Riccetti, S., Sinigaglia, A., & Barzon, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052356 · Cited by 16
COVID-19 vaccines: Frequently asked questions and updated answers
Lefebvre, M., Vignier, N., Pitard, B., Botelho-Nevers, É., Wyplosz, B., Cohen, R., & Épaulard, O. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.02.007 · Cited by 16
Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias
Álvarez, F. V., Martínez‐García, M. Á., Jiménez, D. G., Fariñas-Guerrero, F., de Lejarazu-Leonardo, R. O., López-Campos, J. L., Blanco‐Aparicio, M., Royo-Crespo, Í., García‐Ortega, A., García, A. T., et al. (2021) · Open Respiratory Archives · doi:10.1016/j.opresp.2021.100097 · Cited by 15
Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease
Shenoy, P. D., Ahmed, S., Shanoj, K. C., Shenoy, V., Damodaran, D., Menon, A. R., Alias, B., SanjoSaijan, Devakumar, D., & Babu, A. S. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05801-9 · Cited by 15
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
Nasonov, E. L., & Avdeeva, A. S. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-384-393 · Cited by 15
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS – CoV ‐2 in an Unvaccinated Cohort
Simón, D., Taşçılar, K., Kleyer, A., Fagni, F., Krönke, G., Meder, C. H., Dietrich, P., Orlemann, T., Kliem, T., Mößner, J., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.42035 · Cited by 18
Distinct gut microbiota and health outcomes in asymptomatic infection, viral nucleic acid test re‐positive, and convalescent COVID‐19 cases
Lin, R., Xiao, M., Cao, S., Sun, Y., Zhao, L., Mao, X., Chen, P., Tong, X., Ou, Z., Zhu, H., et al. (2022) · mLife · doi:10.1002/mlf2.12022 · Cited by 15
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection
Schuh, A. J., Satheshkumar, P. S., Dietz, S., Bull–Otterson, L., Charles, M. D., Edens, C., Jones, J. M., Bajema, K. L., Clarke, K. E. N., McDonald, L. C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01247-22 · Cited by 15
Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination
Davenport, B., Morrison, T. E., Kedl, R. M., & Klarquist, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100195 · Cited by 15
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
Capetti, A. F., Borgonovo, F., Mileto, D., Gagliardi, G., Mariani, C., Lupo, A., Dedivitiis, G., Meraviglia, P., Pellicciotta, M., Armiento, L., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.023 · Cited by 15
Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers—Orchestra Project
Violán, C., Carrasco-Ribelles, L. A., Collatuzzo, G., Ditano, G., Abedini, M., Janke, C., Reinkemeyer, C., Thi, T. G. L., Liviero, F., Scapellato, M. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11081340 · Cited by 14
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
Bert, N. L., & Samandari, T. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01127-z · Cited by 16
Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review
Mink, S., Reimann, P., & Fraunberger, P. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1487 · Cited by 14
Does COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?
Doulberis, M., Papaefthymiou, A., Kotronis, G., Gialamprinou, D., Soteriades, E. S., Kyriakopoulos, A. M., Chatzimichael, E., Kafafyllidou, K., Liatsos, C. N., Chatzistefanou, I., et al. (2021) · Medicina · doi:10.3390/medicina57030253 · Cited by 14
Prospective Clinical Assessments of Hospitalized Patients With Positive SARS-CoV-2 PCR Tests for Necessity of Isolation
Rhee, C., Baker, M. A., Kanjilal, S., Tucker, R. P., Vaidya, V., Badwaik, A., Blaeser, E. M., Coughlin, C., Elloyan, J., Hsieh, C., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab194 · Cited by 14
Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots
Turgeon, C. T., Sanders, K. A., Rinaldo, P., Granger, D., Hilgart, H. R., Matern, D., & Theel, E. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252621 · Cited by 14
Persistence of humoral response upon SARS‐CoV‐2 infection
Knies, A., Ladage, D., Braun, R. J., Kimpel, J., & Schneider, M. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2272 · Cited by 17
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Emergence of Two Distinct SARS-CoV-2 Gamma Variants and the Rapid Spread of P.1-like-II SARS-CoV-2 during the Second Wave of COVID-19 in Santa Catarina, Southern Brazil
Padilha, D. A., Filho, V. B., Moreira, R. S., Soratto, T. A. T., Maia, G. A., Christoff, A. P., Barazzetti, F. H., Schörner, M. A., Ferrari, F. L., Martins, C. L., et al. (2022) · Viruses · doi:10.3390/v14040695 · Cited by 14
SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria
Marinov, G. K., Mladenov, M., Rangachev, A., & Alexiev, I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274509 · Cited by 14
Machine-learning-aided multiplexed nanoplasmonic biosensor for COVID-19 population immunity profiling
Beisenova, A., Adi, W., Bashar, S. J., Velmurugan, M., Germanson, K. B., Shelef, M. A., & Yesilköy, F. (2023) · Sensors & Diagnostics · doi:10.1039/d3sd00081h · Cited by 14
COVID-2019 fundamentals
Lamberghini, F., & Testai, F. D. (2021) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2021.01.014 · Cited by 15
Rheumatology and COVID-19 at 1 year: facing the unknowns
Calabrese, L. H., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-219957 · Cited by 14
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
Speer, C., Morath, C. P., Töllner, M., Buylaert, M., Göth, D., Nußhag, C., Kälble, F., Schaier, M., Grenz, J., Kreysing, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.721286 · Cited by 13
Simulation and prediction of spread of COVID-19 in The Republic of Serbia by SEAIHRDS model of disease transmission
Stanojević, S., Ponjavić, M., Stanojević, S., Stevanović, A., & Radojičić, S. (2021) · Microbial Risk Analysis · doi:10.1016/j.mran.2021.100161 · Cited by 14
Incidence of COVID-19 recurrence among large cohort of healthcare employees
Fitzpatrick, V., Rivelli, A. L., Blair, C., Copeland, K., & Richards, J. (2021) · Annals of Epidemiology · doi:10.1016/j.annepidem.2021.04.005 · Cited by 13
Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States
Damluji, A. A., Wei, S., Bruce, S. A., Haymond, A. N., Petricoin, E. F., Liotta, L. A., Maxwell, G. L., Moore, B. C., Bell, R., Garofalo, S., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100030 · Cited by 13
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection
Tyner, H. L., Burgess, J. L., Grant, L., Gaglani, M., Kuntz, J. L., Naleway, A. L., Thornburg, N. J., Caban-Martinez, A. J., Yoon, S. K., Herring, M. K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1038 · Cited by 13
Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study
Rothberg, M. B., Kim, P., Shrestha, N. K. M., Kojima, L., & Tereshchenko, L. G. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac604 · Cited by 13
Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months
Lea, C. S., Simeonsson, K. L., Kipp, A. M., McNeill, C., Wilcox, L., Irish, W. D., Morris, H., Diaz, O., Fallon, J. T., & Roper, R. L. (2022) · Vaccines · doi:10.3390/vaccines10091532 · Cited by 13
Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents
Patalon, T., Saciuk, Y., Hadad, H. O., Peretz, A., Peretz, A., Ben‐Tov, A., & Gazit, S. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.02.016 · Cited by 13
Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data
Reynolds, S. L., Kaufman, H. W., Meyer, W. A., Bush, C., Cohen, O. J., Cronin, K. A., Kabelac, C. A., Leonard, S., Anderson, S., Petkov, V. I., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280584 · Cited by 13
Risk of SARS-CoV-2 Reinfection by Vaccination Status, Predominant Variant, and Time from Previous Infection: A Cohort Study in Italy
Vicentini, M., Venturelli, F., Mancuso, P., Bisaccia, E., Zerbini, A., Massari, M., Cossarizza, A., Biasi, S. D., Pezzotti, P., Bedeschi, E., et al. (2022) · Eurosurveillance · doi:10.2139/ssrn.4132329 · Cited by 13
Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut
Papasavas, P. K., Olugbile, S. O., Wu, U., Robinson, K. J., Roberts, A. L., O’Sullivan, D. M., McLaughlin, T., Mather, J., Steinberg, A. C., Orlando, R., et al. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.04.021 · Cited by 13
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
Perkmann, T., Perkmann‐Nagele, N., Mucher, P., Radakovics, A., Repl, M., Köller, T., Jordakieva, G., Wagner, O. F., Binder, C. J., & Haslacher, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.063 · Cited by 12
Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection
Byrne, J., Gu, L., Leon, A. A. G., Gaillard, C. M., Saini, G., Alalwan, D., Tomás‐Cortázar, J., Kenny, G., Donohue, S., Reynolds, B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445653 · Cited by 12
SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers
Córdova, E., Bacelar, B., Nieto, F., Garibaldi, F., Aguirre, V., Machuca, M., Badia, M. M., & Rodriguez, C. D. L. M. (2021) · Occupational Medicine · doi:10.1093/occmed/kqab061 · Cited by 12
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
Psichοgiou, M., Karabinis, A., Poulakou, G., Antoniadou, A., Kotanidou, Α., Degiannis, D., Pavlopoulou, I. D., Chaidaroglou, A. S., Roussos, S., Mastrogianni, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9091017 · Cited by 13
Maternal-Fetal Immunologic Response to SARS-CoV-2 Infection in a Symptomatic Vulnerable Population: A Prospective Cohort
Larcade, R., DeShea, L., Lang, G. A., Caballero, M. T., Ferretti, A. J. P., Beasley, W. H., Tipple, T. E., Vain, N. E., Prudent, L. M., Lang, M. L., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab591 · Cited by 12
Evidence of SARS-CoV-2 symptomatic reinfection in four healthcare professionals from the same hospital despite the presence of antibodies
Gargouri, S., Souissi, A., Abid, N., Chtourou, A., Fki‐Berrajah, L., Karray, R., Kossentini, H., Ayed, I. B., Abdelmoula, F., Chakroun-Walha, O., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.006 · Cited by 12
Hybrid Modeling of Regional COVID-19 Transmission Dynamics in the U.S.
Bai, Y., Safikhani, A., & Michailidis, G. C. (2022) · IEEE Journal of Selected Topics in Signal Processing · doi:10.1109/jstsp.2022.3140703 · Cited by 12

Authors: Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., Peck, L. J., Ritter, T. G., de Toledo, Z., Warren, L., Axten, D., Cornall, R. J., Jones, E. Y., Stuart, D. I., Screaton, G., Ebner, D., Hoosdally, S., Chand, M., Crook, D. W., O’Donnell, A.-M., Conlon, C. P., Pouwels, K. B., Walker, A. S., Peto, T. E. A., Hopkins, S., Walker, T. M., Jeffery, K., & Eyre, D. W.
Affiliations: Public Health England (GB)
From Oxford University Hospitals NHS Foundation Trust (S.F.L., N.E.S., P.C.M., S.C., T.J., F.W., L.W., D.A., A.-M.O., K.J.), Nuffield Department of Medicine (S.F.L., D.O., N.E.S., P.C.M., A.H., S.B.H., B.D.M., R.J.C., E.Y.J., D.I.S., G.S., D.E., S. Hoosdally, D.W.C., C.P.C., A.S.W., T.E.A.P., T.M.W.), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (N.E.S., P.C.M., S. Hoosdally, D.W.C., A.S.W., T.E.A.P., D.W.E.), the Kennedy Institute of Rheumatology Research (B.D...
Corresponding author: Eyre, David W.
ORCID: Lumley, Sheila F.
Stoesser, Nicole E.
Matthews, Philippa C.
Hatch, Stephanie B.
Marsden, Brian D.
Peck, Liam J.
Ritter, Thomas G.
Cornall, Richard J.
Stuart, David I.
Screaton, Gavin
Ebner, Daniel
Hoosdally, Sarah
Chand, Meera
Crook, Derrick W.
Conlon, Christopher P.
Pouwels, Koen B.
Walker, A. Sarah
Peto, Tim E.A.
Hopkins, Susan
Jeffery, Katie
Eyre, David W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-02-11
Volume: 384
Issue: 6
Pages: 533-540
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2034545
PMC: PMC7781098
OpenAlex: W3117382778
Cited by: 940
References: 29
Citations by year: 2026: 7 · 2025: 26 · 2024: 53 · 2023: 103 · 2022: 299 · 2021: 434
FWCI: 28.01
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: U.K. Government
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, COVID-19 reinfection, healthcare workers, anti-spike IgG, seropositivity, seroconversion, asymptomatic infection, symptomatic infection, infection incidence, antibody status
MeSH terms: Seroconversion, COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, United Kingdom, Health Personnel, Humans, Immunoglobulin G, Longitudinal Studies, Male, Middle Aged, Recurrence, Incidence, Polymerase Chain Reaction, Young Adult, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks